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Abstract—The objective of this work is the systematic study
of the use of electrochemical readout for advanced diagnosis and
drug monitoring. Whereas to date various electrochemical prin-
ciples have been studied and successfully tested, they typically
operate on a single target molecule and are not integrated in a
full data analysis chain. The present work aims to view various
sensing approaches and explore the design space for integrated
realization of multi-target sensors and sensor arrays.
Index Terms—biosensor, integrated circuit, metabolite, oxidase,
cytochrome P450, potentiostat.
I. INTRODUCTION
Electrochemical detection of biological agents is important
in several domains, including the medical practice, the discov-
ery of biological mechanism and monitoring the environment.
To date, several medical devices use electrochemical detection.
A notable case is the family of FDA-approved devices for
glucose monitoring. Most existing systems consists of the the
combination of fluidic systems, sensors and electronic circuits.
Our final objective is the creation of fully-integrated sensors.
To achieve this goal, we focus our attention on integrating
sensing and readout systems.
There are several examples of integrated biosensors. Several
works deal with integrated chips for label-free DNA detection
by using capacitance measurements [1], or by means of
redox couples [2]. Integration is also the key-point to develop
implantable biosensors for long-term monitoring of different
compounds [3], [4], [5], [6]. In the medical practice, existing
FDA-approved sensors are not fully integrated. A notable
example is the GlucoMen R©Day, which can provide real-
time measurements of subcutaneous glucose for up to 100
hours [7]. There are several architectures and technologies for
integrated biosensors, and most devices are designed with ad
hoc methods. Moreover the current need of multiple-target
biosensing requires an extension of the existing techniques.
Thus, the proliferation of electronic monitoring techniques
would benefit from a systematic design space exploration, in
the search of the most cost-effective solution (e.g., small, low
energy consumption, low-cost) to a given problem. In this
paper we propose the use of a platform, i.e., a restriction of
the design space to the use of a small number of parametrized
components, to cope with the design of integrated multiple-
target biosensors.
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A. Medical motivation
Monitoring human metabolism is of crucial importance
for personalized medicine. Many metabolic diseases may be
monitored by means of different endogenous metabolites.
On the other hand, metabolism of exogenous compounds
can enhance the specificity of a therapy according to the
individual patient, since the response rate of different patients
to the same pharmacological treatment and dose typically
varies in the range from 20% to 50%. Bio-monitoring can be
effectively used to tune the dosage of a therapy.
Among endogenous metabolites the most interesting are
glucose, lactate, glutamate, and cholesterol. Glucose amount
in the human blood is a marker for diabetes. Lactic acidosis is
one of the effect of Von Gierke’s disease and it occurs when
mitochondria cannot satisfy cell demand of ATP, especially
during physical efforts or diseases. Glutamate is a neurotrans-
mitter, which can be found in neuronal and glial membranes.
In brain injury or brain diseases, glutamate can accumulate
outside cells, leading to neuronal damage and, eventually, cell
death. Cholesterol is a lipid, and it is one important building
block in the structure of cells. However, high levels in the
blood are strongly associated to atherosclerosis.
Many exogenous metabolites are relevant molecules com-
monly used in drug therapy. Etoposide, ftorafur, cy-
clophospamide, ifosfamide, etc. are well known molecules
typically used in chemotherapy treatments. The measure of
their level in the blood during pharmacological therapy allows
doctors to monitor how the patient is metabolizing the supplied
drugs.
B. Electrochemical principles
Enzymes are very useful proteins, which may be used as
probes to monitor metabolites in case of both endogenous and
exogenous molecules. In particular, the protein class of oxi-
dases may be used for sensing endogenous metabolites, while
cytochromes P450 may be used for sensing drug compounds.
The term oxidase is referred to a large family of enzymes that
catalyzes an oxidation-reduction reaction, involving molecular
oxygen (O2) as the electron acceptor. In these reactions,
the final products can be water (H2O), as well as hydrogen
peroxide (H2O2).
Oxidases are typically characterized by a prosthetic group
integrated within the enzyme, which is the group directly
involved in the redox reaction. For such enzymes like glucose
oxidase (GOD), L-glutamate oxidase (GlOD), and cholesterol
TABLE I
LIST OF OXIDASES USED TO DEVELOP BIOSENSORS.
Oxidase species Target Description
Applied potential
molecule (vs Ag/AgCl)
GLUCOSE
glucose
Metabolic compound
+550 mV [8]
OXIDASE as energy source
LACTATE
lactate
Metabolic compound as
+650 mV [9]
OXIDASE marker of cell suffering
L-GLUTAMATE
glutamate Excitatory neurotransmitter +600 mV [10]
OXIDASE
CHOLESTEROL
cholesterol
Metabolic compound that
+700 mV [11]OXIDASE establishes proper membrane
permeability and fluidity
oxidase (COD), the prosthetic group is the flavin adenine
dinucleotide (FAD) group. FAD can be reduced to FADH2 by
accepting two hydrogen atoms. Then, the reduced form can be
oxidized to restore the initial structure, combining hydrogen
(H+2 ) with O2 and loosing two electrons to produce hydrogen
peroxide. The redox reaction for all these types of enzyme
with FAD as prosthetic group is the following:
FAD + substrate→ FADH2 + product (1)
FADH2 +O2 → H2O2 + FAD (2)
Another subclass of enzymes (lactate oxidase, for example)
employs flavin mononucleotide (FMN) group, which works in
the same way as FAD. For both the prosthetic groups, the final
product of the reaction is the hydrogen peroxide, which is an
electrochemical active species. The following reaction
2H2O2 → 2H2O +O+2 + 4e− (3)
is promoted by applying a potential to the electrochemical cell.
Cytochrome P450 (CYP) belongs to a family of heme
proteins which metabolize over 200,000 chemicals, including
drugs. Since the liver is the main biotransforming organ
for drugs, CYPs and other metabolizing enzymes reside in
the hepatocytes. As FAD and FMN were the active groups
involved in the electron exchange for oxidase, the heme group
has an analogous role for cytochromes. The most common
redox reaction for this family of proteins is described as
follows:
substrate+O2 + 2H
+ + 2e− → product+H2O (4)
where the supplier of electrons is the heme group. Thus,
it is possible to follow the catalytic cycle of cytochrome
by monitoring the electron transfer between the electrode
and the enzyme by using an amperometric biosensor. On
this basis, it is possible to determine the concentration of
the target molecule by measuring the current generated in
the electrochemical cell. There are two main electrochemical
techniques to measure target concentration, according to the
biological agent used in the sensing mechanism.
The common product of oxidases is H2O2, as mentioned
before. The oxidation of hydrogen peroxide is well known
[22] and can be measured by setting the electrode potential
at +650 mV. For this reason it is possible to apply a con-
TABLE II
LIST OF CYTOCHROMES USED TO DEVELOPED BIOSENSORS AND THEIR
ELECTROCHEMICAL PARAMETERS.
CYP Target
Description
Reduction potential
species drug (vs Ag/AgCl)
CYP1A2 clozapine Antipsychotic used in the -265 mV [12]
treatment of schizophrenia
CYP3A4 erythromicin Broad-spectrum antibiotic -625 mV [13]
indinavir
Used in the treatment
-750 mV [14]
of HIV infection and AIDS
CYP11A1
cholesterol
Metabolite able to establish
-400 mV [15]proper cell membrane
permeability and fluidity
CYP2B4
benzphetamine
Used in the treatment
-250 mV [16]
of obesity
aminopyrine
Analgesic, anti-inflammatory,
-400 mV [17]
and antipyretic drug
CYP2B6 bupropion Antidepressant -450 mV [18]
lidocaine Anesthetic and antiarrhythmic -450 mV [19]
CYP2C9 torsemide Diuretic -19 mV [20]
diclofecan Anti-inflammatory -41 mV [20]
CYP2E1
p-nitrophenol
Intermediate in the
-300 mV [21]
synthesis of paracetamol
stant potential, corresponding to the oxidation potential, and
recording the current generated, which is directly proportional
to the concentration of the target molecule metabolized by the
oxidase. This technique is called chronoamperometry, because
the current is monitored as a function of time. With screen-
printed electrodes, the current decays over the time, and it
reaches an approximately steady-state after a certain time.
Another technique used in electrochemistry is called cyclic
voltammetry (CV), and it is more suitable in the case of CYT
P450, where it is possible to identify more target molecules
with the same biological actuator. In fact, by using CV it is
possible to identify multiple targets and their concentration at
the same time. Cyclic voltammetry applies a linear-sweep po-
tential forward and backward within a potential window to the
electrochemical cell, and monitoring continuously the current.
The resulting graph will rise very slowly at the beginning. As
soon as the potential approaches the reduction potential, the
electron transfer from the protein to the electrode increases its
rate, which causes cell current to increase. At a certain point,
the current will start to decrease again, due to the decreasing
rate of diffusion of the target from the bulk of the solution.
Typically, the current is plotted as function of the voltage
and the plot is characterized by some peaks, whose height is
proportional to the target concentration, while position gives
information on the type of molecules that are oxidized, like an
electrochemical signature. Table I summarizes some examples
of oxidases used to develop biosensors, where chronoamper-
ometry is used as the electrochemical technique used for the
detection of hydrogen peroxide (applying a potential around
+650 mV). Table II reports some target molecules, detectable
by CYP and their typical reduction potential.
II. PHYSICAL DESIGN OF THE SENSOR
Chronoamperometry and cyclic voltammetry require elec-
trochemical cells consisting of three electrodes: i) a working
electrode (WE), ii) a reference electrode (RE) and iii) a
counter electrode (CE). A potentiostat circuit keeps the electric
potential of the reference and working electrodes - as well as
the interposed fluid - to a value that can be fixed or variable
with respect to ground. The current that flows to ground
through the working electrode is collected and measured.
When considering sensing multiple targets, it is possible
to consider various bio-electrical interfaces. The simplest
physical structure is a single sensor, made of 3 electrodes, with
WE that is functionalized with enzymes to sense one or more
targets. An extension of this sensor for n targets, is to use n+2
electrodes, out of which there are n working electrodes each
functionalized for a given target. An underlying assumption
for this sensor to be useful is that the targets can be present
in the same volume surrounding the probe without interfering.
A one-dimensional (or two-dimensional) sensor array consists
of k (or k x j) such sensors, each with 3 or more electrodes.
Finally, when the electrochemical reactions must be kept
separated, each sensor in an array must have its own chamber.
A. Sensor design for multiple targets
In this section we want to consider jointly: i) the choice of
the probe; ii) the choice of the sensor structure; iii) the choice
of electronic readout circuitry. We start from the choice of
the probe, as this is typically dictated by the target, and the
target is often the objective of the biomedical investigation.
Let us consider first oxidase-based sensing. In this
case, quantitative measures are obtained from the current
generated by the oxidation of hydrogen peroxide. In a first
approximation it is possible to combine more oxidases in
the same chamber to detect different metabolites, even if all
the oxidases generate current by oxidation of the hydrogen
peroxide. Since the diffusion coefficient of H2O2 is really
low, we can assume negligible cross-talk among the different
sensors. Otherwise, we should consider separate chambers,
where an array of electrochemical cells achieve the multi-
target sensing.
Next, let us consider CYP-based sensing. As mentioned
before, the simplest CYP measure consists in a cyclic
voltammetry, i.e., by cycling the potential of the fluid
interposed between the RE and WE, and by measuring the
current flowing out of the WE. According to the cytochrome
isoform chosen, one or more targets can be detected by
current peaks corresponding to the related electrochemical
potentials. Thus, a single probe can sense multiple targets, if
the I/V plot can be recorded in correspondence with current
maxima.
An alternative approach to multiple target detection can
be achieved by sensors with more than one WE, each
characterized by a different probe. In this case, cyclic
voltammetry sweeps the potential of the fluid between RE
and WE, and currents stemming out of the WEs will display
peaks in correspondence with the related voltammetric
potentials. A circuit sensing the corresponding currents -
possibly multiplexed - and their maxima is then needed. It is
important to remark that the collected currents relate to the
amount of target interacting with the probe, and thus multiple
measures can be done in a single chamber.
The use of sensor arrays - with or without multiple
chambers - is a straightforward extension. From an electronic
standpoint, an issue is the ability to share hardware resources
(such as voltage generators) and current sensors, possibly by
multiplexing. As an example, De Venuto et al. showed how
to multiplex the measurement of the currents coming from
various probes, to sense concentrations of different molecules
[23].
B. Properties
We list here the desirable properties of a biosensing acqui-
sition chain.
• Limit of detection (LOD). It is the lowest quantity of a
substance that can be distinguished from the absence of
that substance (a blank value) within a stated confidence
limit. The detection limit is estimated from the mean of
the blank Vb, the standard deviation of the blank σb, and
some confidence factor. ACS committee on environmen-
tal improvement recommends the following definition to
calculate LOD [24]:
LOD = Vb + 3σb (5)
in order to have a definite risk of less than 7% for false
positive.
• Sensitivity. It is the slope of the calibration curve, i.e.
(Vss- Vb) versus the analyte concentration, c, or its
logarithm [25], where Vss is the steady-state response.
Global sensitivity is due to the cascading effects of the
i) electrochemical reaction, ii) electron collection, iii)
current amplification and conversion. The average global
sensitivity, Savg can be defined as:
Savg = ∆V/∆C (6)
where ∆C is the measured range of analyte concentration
and ∆V is the corresponding change in the output signal
of the system.
• Linear concentration range and linearity. On the biosen-
sor side, linear range is directly related to the biocatalytic
or biocomplexing properties of the biochemical or biolog-
ical receptor [25]. In the system level, the effects of the
bioprobes membrane and electronics readout should be
considered as well in limiting the linearity. The maximum
non-linearity of a measurement platform can be defined
as:
NLmax = max|VC − VC0 − Savg · (C − C0)| (7)
where C0 refers to a reference concentration, VC and
VC0 are the output signals corresponding to C and C0
concentrations.
• Selectivity. It measures the ability to discriminate between
different substances. Such behavior is principally a func-
tion of the recognition element, i.e. the enzymes [22].
Fig. 1. A simple block diagram of a potentiostat and a transimpedance
amplifier.
• Steady-state response time. It is the time necessary to
reach 90% of the steady-state response. Transient re-
sponse time corresponds to the time necessary for the first
derivative of the output signal to reach its maximum value
(dV/dt)max following the analyte addition. Both response
times depend upon the analyte, co-substrate and product
transport rates through different layers or membranes.
They also depend upon the activity of the molecular
recognition system and the mixing conditions of the
sample into the batch measurement cell [25]. Since the
biochemical sensing is a very slow process, the readout
circuitry would not limit the response times of the output
signal.
• Sample throughput. It is a measure of the number of
individual samples per unit of time. This parameter takes
into account both the transient response time and the
recovery time, i.e. the time needed for the signal to return
to its baseline [25].
In the sequel, we concentrate on the following parameters:
1) limit of detection, 2) sensitivity, 3) linearity and 4) time
response, because they affect the design of the electronic
building blocks.
C. Electrical building blocks for biosensing
We restrict our attention to biosensing achieved by oxidases
and CYP by means of observing a current while controlling
potentials.
Major building blocks are:
• A current readout circuit that can sense currents in the
range of +/-10uA with 10nA resolution for oxidases, and
the range of +/-100uA with 100nA resolution for CYP,
and translate it into a voltage that can be digitized through
an ADC.
• A potentiostat circuit that has the purpose of keeping
the reference and working electrode, as well as the
surrounded fluids, at a given potential with respect to
ground. One of the possible potentiostat configurations is
shown in Fig. 1.
• A voltage generator that generates a fixed or variable
voltage to feed the potentiostat circuit. For single-target
chronoamperometry, the voltage is fixed and chosen on
the basis of the electrochemical reaction. For cyclic
voltammetry, this circuit sweeps repeatedly within the
voltage range of interest.
Fig. 2. Building block diagram for a biosensing platform.
• Multiplexing circuits to support the readout of multiple
current sources and the drive of multiple control points
for the potential.
A building block diagram for a biosensing platform is shown
in Fig. 2.
Different approaches to readout can be used. We describe here
the fundamental principles and their limitations. The most
straightforward approach is to convert the biosensor current
into voltage using a transimpedance amplifier as shown in Fig.
1. As the current levels are low, specific techniques can be used
such as using current mirrors, multi-stage amplification and/or
switched-capacitor circuits. Alternative approaches convert
currents to the frequency domain [26], [27] .
The amplification stage has to satisfy some characteristics,
such as linearity, step response and low-noise. Whereas all
these are typical of data acquisition schemes, particular atten-
tion has to be given to noise issues. The sensor noise is hard to
quantify analytically, but it can be measured experimentally.
The amplifier input noise has to be made negligible as com-
pared to the sensor node. Particular care has to be taken for the
Flicker (or 1/f ) noise component, which can be reduced by
techniques such as chopping and Correlated Double Sampling
(CDS). Chopping involves moving the signal of interest to
a higher frequency before amplification. In CDS, the output
of the sensor is measured twice: once in a known condition
and once in an unknown condition. The value measured from
the known condition is then subtracted from the unknown
condition to generate a value with a known relation to the
molecule concentration being measured. The latter can be
realized using an extra WE without any enzyme on it. Note
that the extra WE is not helpful in presence of molecules such
as Dopamine and Etoposide, as they can oxidize by applying
a voltage to the WE even without any enzyme.
In cyclic voltammetry, the rate of voltage variation affects
the accuracy of measurement. The electrochemical cell reacts
only to slow potential variations of about 20 mV/sec. If the
voltage changes too rapidly, the biosensor current peak does
Fig. 3. Time-response example for a glucose biosensor.
not occur at the specific potential of the target molecule
anymore, making it hard to distinguish among different targets.
An example of time response for a glucose biosensor is
depicted in Fig. 3. We can notice that the signal takes around
30 seconds to reach the steady-state after an injection of the
target molecule. As data acquisition deals specifically with
slow signals in our case, noise and drift control (e.g. stability)
at low frequencies is very important.
III. A PLATFORM EXAMPLE
Different strategies have been proposed to develop inte-
grated biosensors. The most common and widely used foresees
to use cheap disposable electrodes, which can be inserted
in a separate device with the integrated electronics [28],
[29]. This approach is unsuitable for long-term implants in
the body. Another technique is to fabricate 3-D integration
chips with a top replaceable bio-layer, as showed by Temiz
et al. [30]. Despite these systems are not yet implantable,
it is possible to jointly fabricate electrodes and electronic
circuits to reduce costs. The third approach involves disposable
electrodes and electronics, which can be thrown away once
a series of measurements is performed. An example is the
Quicklab R© system by Siemens.
Figure 4 shows the biointerface of our platform. Scal-
ing down the electrodes can bring some advantages: the
background current is smaller, due to different double-layer
capacitance phenomena[22]; time response of the biosensor
is decreased in the case of microelectrodes, enabling much
shorter measurements [22]. In the proposed configuration, the
different working electrodes share the same counter and ref-
erence electrodes, so it is necessary to multiplex the signal of
the working electrodes, in order to activate them sequentially.
The bio-interface layer consists of five working electrodes,
one counter and one reference electrode. Working and counter
electrodes are made of a thin film of gold, while reference
electrode is made of silver, both metals deposited on silicon
by metal evaporation. A layer of SiO2 is used as passivation on
the top of the electrical connections. The electrode area is 0.23
mm2, but can be further decreased. Electrical connection with
the rest of the instrumentation is guaranteed by the pads, which
match with an out-of-shelf interface. The whole device can be
further miniaturized. Working electrodes can be functionalized
Fig. 4. An example of platform with multi-working electrodes.
by nanostructures, to increase sensitivity [15]; by polymers, to
provide long-term stability [3]; and by the enzyme probe to
enhance selectivity.
To achieve multi-panel metabolite detection, we can func-
tionalize the 5 working electrodes to detect glucose, lactate,
glutamate, benzphetamine, or aminopyrine, and cholesterol.
Oxidases can be the probe for the first three compounds,
while cytochromes are able to detect the other compounds
(as already discussed in Table II). Note that with the same
agent (CYP2B4) it is possible to detect different compounds
(benzphetamine and aminopyrine) at the same electrode, due
to the fact that the two molecules oxidize at different potential.
The hight of the two corresponding peaks gives information
about their concentration. Taking into account the discussion
in Section II-B, Table III resumes the main properties of
each functionalized electrode. Regarding glucose, lactate and
glutamate detection, the values reported in the table are ob-
tained in the case of single working electrodes nanostructured
with carbon nanotubes. Benzphetamine and aminopyrine are
measured on rhodium graphite electrodes [16], while choles-
terol onto carbon nanotubes-based electrode [15]. All the
mentioned functionalization and nanostructuration protocols
can be easily integrated onto the developed platform and
achieved by proteomic spotting.
With the present configuration, it is necessary to employ
a fixed or variable voltage generator, according to the func-
tionalization of each electrode. We need also a multiplexer,
which switches sequentially among the different working
electrodes. Finally, the current readout depends also on the
type of functionalization, since oxidases do not need a current
peak detector. Note from Table III that the introduction of a
nanostructuration on the electrodes brings much larger signals,
demanding less constrains for the readout circuit. On the other
hand, benzphetamine and aminopyrine have a much lower
sensitivity with respect to the other values, which can be
further enhance by employing nanostructured electrodes.
IV. CONCLUSION
The aim of the present work is to consider the different
aspects for the development of a fully integrated platform for
the detection of endogenous and exogenous metabolites for
advanced diagnostics. Sensing multiple targets is of crucial
importance for personalized therapy. We have resumed the
TABLE III
PERFORMANCE OF DIFFERENT METABOLITE BIOSENSORS.
Target Probe
Sensitivity Limit of Linear
(µA/(mM cm2)) detection (µM) range (mM)
GLUCOSE
glucose
27.7 575 0.5 - 4
oxidase
LACTATE
lactate
40.1 366 0.5 - 2.5
oxidase
GLUTAMATE
glutamate
25.5 1574 0.5 - 2
oxidase
BENZPHETAMINE
CYP2B4
0.28 200 0.2 - 1.2 [16]
AMINOPYRINE 2.8 400 0.8 - 8 [16]
CHOLESTEROL CYP11A1 112 — 0.01 - 0.08 [15]
electrochemical principles for oxidases and cytochromes, two
enzyme families which can detect the majority of human
metabolites. We have reviewed different sensor configurations
according to the different strategies of detection. We have ana-
lyzed the desirable properties of a biosensing acquisition chain.
We have presented an electrical building block for multiple
metabolite detection, discussing the implications between a
given design and biosensor features. Finally, we have described
the biointerface of a platform for the detection of endogenous
and exogenous compounds.
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